Paul-Flechsig-Institut für Hirnforschung
 Universitätsmedizin Leipzig

Innovative treatment of Alzheimer's disease and related disorders - Concept for a somatic gene therapy

Alzheimer's disease (AD) and stroke giving rise to vascular dementia (VD) are most prominent causes for mental impairment in the adult and elderly. AD and stroke share a cell death pathway that is activated by unscheduled neuronal cell cycle re-entry and subsequent partial replication of DNA.

Moreover, in AD, we could provide direct evidence for the selective cell death of neurons which have replicated their DNA. This directly proofs the link between cell cycle activation and cell death in neurons of the adult human central nervous system (CNS) and identifies the molecular control of cell cycle activation as therapeutic target. With this project, we aim to further develop a therapeutic concept of neuroprotection to slow down or even prevent cell death by neuron-specific targeting of the cell cycle by somatic gene therapy. The approach will also be applicable to other neurodegenerative disorders and non-neuronal disorders with unscheduled cell-cycle activation, such as cancer or atherosclerosis.



  • Amarantus BioScience Holdings, Inc. (AMBS)


granted Patents:  EP2620447 (B1); KR101378353 (B1); applied Patents:  WO2010089122 (A3);  AU2010211289 (A1);   CA2751531 (A1);   CN102356156 (A);  US2012004277 (A1)

last update: 12.01.2017, 10:06 Uhr
Zurück zum Seitenanfang springen
Zurück zum Seitenanfang springen
Paul-Flechsig-Institut für Hirnforschung